Neo Kuma Ventures

Type

Venture Capital

Status

Active

Location

London, United Kingdom

Total investments

6

Average round size

3M

Portfolio companies

6

Rounds per year

1.50

Lead investments

1

Stages of investment
SeedEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyInformation TechnologyE-LearningHealth CareTrainingEducationMedicalPharmaceuticalPsychology

Investor highlights

Industry focus
HealthcareBiotech/Life SciencesMedtechWellness & Fitness
Stage focus
Pre-SeedSeedSeries A
Geo focus
Generalist
Check size
188K — 1M

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
GBP 3000000
Fund raised date
2020-06-01

Analytics

Total investments
6
Lead investments
1
Rounds per year
1.50
Investments by industry
  • Health Care (3)
  • Biotechnology (2)
  • Medical (1)
  • Information Technology (1)
  • E-Learning (1)
  • Show 4 more
Investments by region
  • United Kingdom (3)
  • United States (2)
Peak activity year
2021

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
2
Group Appearance index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Monument Therapeutics 01 Jul 2021 Biotechnology, Health Care, Pharmaceutical Seed 3M Cambridgeshire, Cambridge, United Kingdom
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.